News | August 19, 2024
CIDSCON 2024 discusses actionable efforts to tackle antimicrobial resistance
The emergence of new infections in India is a growing concern
The emergence of new infections in India is a growing concern
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The inspection was concluded with zero observations
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Subscribe To Our Newsletter & Stay Updated
